Marjanska Agata, Galazka Przemyslaw, Marjanski Michal, Wysocki Mariusz, Styczynski Jan
Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland
Department of General and Oncological Surgery for Children and Adolescents, Nicolaus Copernicus University Torun, Jurasz University Hospital, Collegium Medicum, Bydgoszcz, Poland.
Anticancer Res. 2019 Jul;39(7):3945-3947. doi: 10.21873/anticanres.13547.
BACKGROUND/AIM: Malignant melanoma is a rare disease in the pediatric population and there are no recommendations regarding its management in children, while the current standard of care in metastatic or unresectable melanoma in adult patients includes immunotherapy (anti-CTLA-4 and anti-PD-1 antibodies). Advances in the management of adults with melanoma offer the prospect of promising therapeutic options for children.
We describe a case of a 7-year-old patient with recurrent metastatic melanoma, for whom pembrolizumab was used as an adjuvant therapy on compassionate use basis.
Due to adverse events, the treatment was discontinued after 5 months of pembrolizumab, but with 12-months of follow-up, patient remains in complete remission.
背景/目的：恶性黑色素瘤在儿童群体中是一种罕见疾病，目前尚无关于儿童黑色素瘤治疗的相关建议，而成人转移性或不可切除黑色素瘤的当前标准治疗方案包括免疫疗法（抗CTLA-4和抗PD-1抗体）。成人黑色素瘤治疗的进展为儿童提供了有前景的治疗选择。
我们描述了一名7岁复发性转移性黑色素瘤患者的病例，该患者在同情用药的基础上使用派姆单抗作为辅助治疗。
由于不良事件，派姆单抗治疗5个月后停药，但经过12个月的随访，患者仍处于完全缓解状态。
Zotero 插件